Despite this, Roberti et al. (2014) were the first to use low-dose cytokine therapy – Guna-Interleukin 4, Guna-Interleukin 10 and Guna-Interleukin 11- at the concentration of 10 fg/mL in psoriasis patients, and showed us the safety and efficacy of this kind of low-dose cytokine combination therapy in 2014. Here, IL10 is linked to psoriasis.